Danaher(US:DHR) ZACKS·2025-10-17 15:21Core Insights - Danaher Corporation (DHR) is set to release its third-quarter 2025 results on October 21, before market open [1][11] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $6.00 billion, reflecting a 3.4% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.72 per share, indicating a 0.6% increase from the year-ago quarter [2] - Danaher has surpassed the Zacks Consensus Estimate in three of the last four quarters, with an average beat of 8.5% [2] Segment Performance - The Life Sciences segment is expected to face challenges due to lower demand in protein consumables, flow cytometry, and lab automation solutions, with revenues projected to increase by 2.5% to $1.83 billion [4] - The Biotechnology segment is anticipated to benefit from strong demand for bioprocessing, with revenues expected to rise 8.9% to $1.80 billion [7] - The Diagnostics segment is likely to see modest growth, with revenues projected to increase by 0.4% to $2.37 billion, driven by the Beckman Coulter Diagnostics unit [8] Cost and Expenses - Danaher is experiencing rising costs, with cost of sales expected to increase by 5.8% year over year to $2.54 billion and SG&A expenses anticipated to rise by 7.7% to $1.53 billion [5] International Exposure - The company has significant exposure to international markets, which may negatively impact profitability due to foreign currency headwinds [6] Recent Acquisitions - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [9] Earnings Prediction - The current Earnings ESP for Danaher is -0.39%, indicating a lower likelihood of an earnings beat this quarter [10]